Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 696-82-2 Chemical Structure| 696-82-2

Structure of 696-82-2

Chemical Structure| 696-82-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 696-82-2 ]

CAS No. :696-82-2
Formula : C4HF3N2
M.W : 134.06
SMILES Code : FC1=CC(F)=NC(F)=N1
MDL No. :MFCD00039705
InChI Key :NTSYSQNAPGMSIH-UHFFFAOYSA-N
Pubchem ID :69677

Safety of [ 696-82-2 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H314-H335
Precautionary Statements:P261-P280-P305+P351+P338-P310
Class:8
UN#:3265
Packing Group:

Computational Chemistry of [ 696-82-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 5.0
Num. H-bond donors 0.0
Molar Refractivity 21.91
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

25.78 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.42
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.5
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.15
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.89
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.33
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.66

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.11
Solubility 1.04 mg/ml ; 0.00777 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.65
Solubility 3.01 mg/ml ; 0.0224 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.46
Solubility 0.468 mg/ml ; 0.00349 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.05 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.95

Application In Synthesis of [ 696-82-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 696-82-2 ]

[ 696-82-2 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 3764-01-0 ]
  • [ 3833-57-6 ]
  • [ 3824-45-1 ]
  • [ 696-82-2 ]
  • 3
  • [ 696-82-2 ]
  • [ 675-12-7 ]
  • [ 675-11-6 ]
  • [ 696-83-3 ]
  • 4
  • [ 696-82-2 ]
  • [ 188528-95-2 ]
  • 3-(2,6-difluoro-pyrimidin-4-yl)-2-oxo-pyrrolidine-1,3-dicarboxylic acid 1-<i>tert</i>-butyl ester 3-ethyl ester [ No CAS ]
  • 3-(2,6-difluoro-pyrimidin-4-yl)-2-oxo-pyrrolidine-1,3-dicarboxylic acid 1-<i>tert</i>-butyl ester 3-ethyl ester [ No CAS ]
  • 5
  • [ 696-82-2 ]
  • [ 675-11-6 ]
YieldReaction ConditionsOperation in experiment
With ammonia; In water; (a) 2-Amino-4,6-difluoropyrimidine 69.7 g (4.1 mol) of liquid ammonia were added at -30 to -20 C. to a stirred mixture of 250 g (1.865 mol) of 2,4,6-trifluoropyrimidine and 3.3 1 of diethyl ether within 1 hour. To work up, the reaction mixture was warmed to 25 C. and the precipitate was filtered off. Washing with ether, stirring in water, renewed filtration and drying resulted in 203 g (83% of theory) of the desired product (melting point 214-216 C.). It was possible by concentrating the ether filtrate to about 1/3 of its volume to isolate a further 20 g (8% of theory) of this compound, of melting point 193-196 C., from a 1:1 mixture with the isomeric 4-amino compound. Comparative experiment (according to SU-A 547,447--1975) Under the same reaction conditions as in (a), but with addition and reaction taking place at -10 C., 100 g (0.746 mol) of 2,4,6-trifluoropyrimidine and 29.1 g (1.71 mol) of ammonia yielded 76 g (78% of theory) of the title compound of melting point 212-213 C., and from the filtrate a further 19.5 g (20% of theory) of a mixture (40:60) of the desired compound and the isomeric 4-amino compound (melting point 195-196 C.).
  • 6
  • [ 5932-27-4 ]
  • [ 696-82-2 ]
  • [ 1439863-64-5 ]
  • 7
  • [ 696-82-2 ]
  • [ 696-83-3 ]
YieldReaction ConditionsOperation in experiment
With ammonium hydroxide; In acetonitrile; at 0 - 40℃; C. Preparation of a Compound of Formula (3) in which R4 is CI, R6 and R7 are H2> and X is F To 2A^trifluoiopyrimidine (10 g, 75 mmol) in acetonitrile (100 mL) cooled to 0C is added cone NH OH (50 mL) in three portions. Remove the cooling bath and allow to stir at room temperature for 6 h followed by heating at 40CC overnight. Remove the solvent in vacuo to give 2,4^iamino~6~fluoropyiisnidine. MeOH EtOH (250 mL, 1:1) is added to the 2,4~diannno-6~ uoiOpyrimidine and the mixture is cooled with an ice bath. NCS (13 g, 97 mmol) was added in portions. The ice bath was removed and the mixture stirred for 6 h, followed by heating to 50C overnight. Approximately 75 mL of the solvent is removed in vacuo and the reaction vessel is cooled to -10C. The solid is collected by filtration and added to water (100 mL) and stirred. The solid is collected by filtration and added to 0.1M NaOH (1 0 mL) and stirred. The solid is collected by filtration to give 2,4-diamino-5~chloro~ 6-flixoropyrimidine.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 696-82-2 ]

Fluorinated Building Blocks

Chemical Structure| 2802-62-2

A578479 [2802-62-2]

4,6-Difluoropyrimidine

Similarity: 0.88

Chemical Structure| 675-11-6

A235020 [675-11-6]

4,6-Difluoropyrimidin-2-amine

Similarity: 0.79

Chemical Structure| 18260-64-5

A503565 [18260-64-5]

4,6-Difluoro-5-methylpyrimidine

Similarity: 0.75

Chemical Structure| 17573-78-3

A128507 [17573-78-3]

4,5,6-Trifluoropyrimidine

Similarity: 0.71

Chemical Structure| 31575-35-6

A106096 [31575-35-6]

2-Fluoropyrimidine

Similarity: 0.70

Related Parent Nucleus of
[ 696-82-2 ]

Pyrimidines

Chemical Structure| 2802-62-2

A578479 [2802-62-2]

4,6-Difluoropyrimidine

Similarity: 0.88

Chemical Structure| 675-11-6

A235020 [675-11-6]

4,6-Difluoropyrimidin-2-amine

Similarity: 0.79

Chemical Structure| 18260-64-5

A503565 [18260-64-5]

4,6-Difluoro-5-methylpyrimidine

Similarity: 0.75

Chemical Structure| 17573-78-3

A128507 [17573-78-3]

4,5,6-Trifluoropyrimidine

Similarity: 0.71

Chemical Structure| 31575-35-6

A106096 [31575-35-6]

2-Fluoropyrimidine

Similarity: 0.70